EP1582220A1 - Composition destinee a une anesthesie topique - Google Patents
Composition destinee a une anesthesie topique Download PDFInfo
- Publication number
- EP1582220A1 EP1582220A1 EP03778778A EP03778778A EP1582220A1 EP 1582220 A1 EP1582220 A1 EP 1582220A1 EP 03778778 A EP03778778 A EP 03778778A EP 03778778 A EP03778778 A EP 03778778A EP 1582220 A1 EP1582220 A1 EP 1582220A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- local
- anesthetic
- hydrochloride
- local anesthesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition for local anesthesia. More specifically, the present invention relates to a safe composition for local anesthesia which has durability of action suitable for minor dental operations such as tooth extraction.
- anesthetics for local injection containing lidocaine (2-diethylamino-N-(2,6-dimethyl-phenyl)acetamide) as an active ingredient have been used.
- lidocaine (2-diethylamino-N-(2,6-dimethyl-phenyl)acetamide
- Xylocaine Cartridge for Dental Use (Fujisawa Pharmaceutical Co., Ltd.) has been clinically used.
- This agent for local anesthesia is a composition for topical administration which contains 20 mg of lidocaine hydrochloride and 0.0125 mg of epinephrine per 1 ml of a solution for injection. The agent is generally used in an amount of 0.3-1.8 ml to carry out infiltration anesthesia or block anesthesia (see, a package insert of the drug).
- Agents for local anesthesia are generally formulated with a catecholamine such as epinephrine which has angiotonic effect on local capillary blood vessels to reduce blood flow.
- the effect of the catecholamine is to decrease bleeding in a field of operation by lowering blood flow, and to reduce transmigration (diffusion) of an anesthetic agent being an active ingredient into blood and maintain high concentration of the anesthetic agent in the local tissue to achieve a prolonged local anesthetic effect (Collins, V. J., Principles of Anesthesiology, 2nd Ed., Lea and Febiger, Philadelphia, 1976; as a review about agents for dental local anesthesia, see, Dental Outlook, special edition, "Medical practice of tooth extraction," 4. Dental local anesthetics, pp.84-94, 1979).
- epinephrine is mixed at 1/80,000 (g/ml, 0.0125 mg per ml).
- anesthetics for dental use containing about 1/200,000 (g/ml) of epinephrine (0.005 mg as a free base per ml) are proposed as compositions for local anesthesia having durability suitable for short-time dental operations such as tooth extraction (WO 97/07794).
- agents for sustaining the action of local anesthetics As for agents for sustaining the action of local anesthetics, it is known that substances selected from the group consisting of acidic mucopolysaccharides such as sodium chondroitin sulfate and cellulose derivatives such as hydroxypropylmethylcellulose have the action of sustaining anesthetic action of local anesthetics such as lidocaine hydrochloride (WO 02/055107). However, almost no substance useful as the agent for sustaining the action of local anesthetics has been known so far other than the aforementioned substances.
- diphenhydramine hydrochloride which is an antihistamine
- diphenhydramine hydrochloride which is an antihistamine
- this substance per se, maintains the action of local anesthetics such as lidocaine hydrochloride.
- solutions for external use, aerosols, ointments and the like for therapeutic treatment of dermatosis containing diphenhydramine hydrochloride and lidocaine hydrochloride are known (Japanese Patent Publication (KOKOKU) No. 7-74152, Japanese Patent Unexamined Publication (KOKAI) No. 11-228398, Japanese Patent Publication No. 61-46451 and the like).
- An object of the present invention is to provide a composition for local anesthesia which has excellent durability of action. More specifically, the object of the present invention is to provide a safe composition for local anesthesia which has durability of action suitable for minor dental operations such as tooth extraction and oral surgery operations without using catecholamines.
- the inventors of the present invention conducted intensive researches to achieve the foregoing objects, and as a result, they found that antihistamines such as diphenhydramine hydrochloride and hydroxyzine hydrochloride have a function to significantly maintain anesthetic action of local anesthetics such as lidocaine hydrochloride.
- the present invention was achieved on the basis of these findings.
- the present invention thus provides a composition for local anesthesia which comprises a local anesthetic as an active ingredient and an agent for sustaining anesthetic action selected from the group consisting of antihistamines, and does not substantially contain catecholamines.
- the aforementioned composition for local anesthesia is preferably provided as a composition for local anesthesia used for oral surgery or dental treatment.
- the aforementioned composition for local anesthesia wherein the local anesthetic is lidocaine hydrochloride; the aforementioned composition for local anesthesia wherein, the antihistamine is an antihistamine having a diphenylmethyl group (the phenyl groups may be substituted or unsubstituted) as a partial structure; and the aforementioned composition for local anesthesia, wherein the antihistamine is diphenhydramine hydrochloride or hydroxyzine hydrochloride.
- the present invention provides an agent for sustaining anesthetic action of a local anesthetic selected from the group consisting of antihistamines.
- a local anesthetic selected from the group consisting of antihistamines.
- the aforementioned agent for sustaining action wherein the local anesthetic is lidocaine hydrochloride; and the aforementioned agent for sustaining action, wherein the antihistamine is diphenhydramine hydrochloride or hydroxyzine hydrochloride.
- the present invention provides use of a substance selected from the group consisting of antihistamines for manufacture of the aforementioned composition for local anesthesia; and a method for sustaining anesthetic action of a local anesthetic comprising the step of topically administering a substance selected from the group consisting of antihistamines together with a local anesthetic.
- Types of the local anesthetics which are comprised in the composition of the present invention are not particularly limited.
- Examples include ***e analogues such as ***e and tropa***e; water-soluble esters of aminobenzoic acid such as procaine and tetracaine; esters of benzoic acid such as piperocaine and stovaine; esters of alkoxybenzoic acid such as cyclomethycaine and parethoxycaine; aminoketones such as dyclonine and falicaine; aminoethers such as pramoxine; benzofuranone derivatives such as amolanone; amidine or guanidine derivatives such as phenacaine; urethane derivatives such as diperodon; quinoline or isoquinoline derivatives such as dibucaine; amino acid anilides such as lidocaine; alkylesters of aminobenzoic acid such as ethyl aminobenzoate.
- ***e analogues such as ***e and tropa***e
- a local anesthetic selected from the group consisting of lidocaine, procaine, tetracaine, dibucaine, and salts thereof may preferably be used. More preferably, a local anesthetic selected from the group consisting of lidocaine hydrochloride, procaine hydrochloride, tetracaine hydrochloride, and dibucaine hydrochloride may be used. Lidocaine hydrochloride may most preferably be used.
- An antihistamine generally means an agent having affinity for a histamine receptor and antagonistically acting on the action of histamine by blocking or suppressing the action of histamine.
- Type of the antihistamine used in the composition of the present invention as an agent for sustaining action of local anesthetics is not particularly limited.
- preferred examples include those having, as a partial structure, a diarylmethyl group (two of the aryl groups in the group may be the same or different, and may be, for example, substituted or unsubstituted phenyl groups, or substituted or unsubstituted heteroaryl groups containing a heteroatom as a ring-constituting atom such as pyridyl group), preferably a diphenylmethyl group (each of the two phenyl groups in the group may be substituted or unsubstituted).
- a substituent on the phenyl groups halogen atoms such as chlorine atom are preferred.
- one chlorine atom substitutes on one phenyl group of the two phenyl groups, and it is more preferred that the chlorine atom is present in the para-position. It is also preferred that two of the phenyl groups are unsubstituted.
- examples of the antihistamine include, for example, diphenhydramine, chlorphenoxamine, carbinoxamine, chlorpheniramine, tolopropamine, homochlorcyclizine, diphenylpyraline, clemastine, hydroxyzine, meclizine, diphenidol and the like. Among them, diphenhydramine and hydroxyzine are preferred. Two or more kinds of antihistamines can also be used in combination. These antihistamines can be used as pharmacologically acceptable salts. Types of the pharmacologically acceptable salts can be suitably chosen by those skilled in the art, and specific examples include, for example, diphenhydramine hydrochloride, diphenhydramine salicylate, hydroxyzine hydrochloride and the like.
- An amount of the agent for sustaining anesthetic action selected from the group consisting of antihistamines can be suitably selected depending on the type of the agent for sustaining anesthetic action, the type of the local anesthetic, the desired duration, anesthetic depth of local anesthesia, and the like, and generally selected to be in the range of approximately 0.1 g to 10 g based on 1 g of local anesthetic.
- Anesthetic duration of the composition for local anesthesia can be objectively and precisely determined by the methods described in, for example, Journal of Japanese Dental Society of Anesthesiology, 16, pp. 10-22, 1988; and Journal of Japanese Dental Society of Anesthesiology, 27, pp. 158-164, 1999, or the method specifically described in Examples of the present specification.
- composition for local anesthesia of the present invention can be provided as a composition for injection in a form of an aqueous solution in which the aforementioned components and optional pharmaceutical additives, which are available for those skilled in the art as additives to be formulated in compositions for topical injections, are dissolved in distilled water for injection.
- the composition for local anesthesia of the present invention can also be prepared as a pharmaceutical preparation in a dried form such as a lyophilized preparation, and dissolved when used.
- the composition is provided for clinical use after being filled in ampoules, vials, cartridges or the like under sterile condition.
- isotonicities to adjust osmotic pressure ratio to about 0.8-1.3, preferably about 1.0, e.g., sodium chloride; pH modifiers to adjust pH to a range of about 3.0-7.5, preferably 3.3-7.0, e.g., hydrochloric acid or sodium hydroxide; antiseptics, e.g., methyl p-hydroxybenzoate, and the like may be used.
- the composition for local anesthesia of the present invention can be suitably used for minor operations in oral surgery and dental treatment, preferably for operations which can be completed in several to ten minutes such as tooth extraction in dental treatment.
- applicable operations are not limited to the uses in the oral surgery and dental treatment, and the composition can be used for surgical local anesthesia such as for skin incision.
- the agent for sustaining action of a local anesthetic contained in the composition of the present invention prolongs duration of the action of a local anesthetic, and has an effect of increasing anesthetic depth as well.
- the composition for local anesthesia of the present invention provides increased depth and durability of local anesthesia without using catecholamines such as epinephrine, and has a feature that the composition can be used as a safe local anesthetic even to patients with hypertonia, anteriosclerosis, cardiac failure, hyperthyreosis, or diabetes or a patient who has experienced angiospasm.
- composition of the present invention can be prepared by a method well known to those skilled in the art. Specific examples of the method for producing the composition of the present invention are detailed in the following examples. However, methods for preparing the composition of the present invention are not limited to those described in the examples, and appropriate alterations and modifications can be added to these methods.
- Diphenhydramine hydrochloride (1 g) and lidocaine hydrochloride (2 g) were dissolved in distilled water for injection (80 ml). After being adjusted to pH 6 by adding a sufficient quantity of sodium hydroxide, the solution was added with distilled water for injection up to the total volume of 100 ml to prepare a composition for local anesthesia.
- Diphenhydramine hydrochloride (2 g) and lidocaine hydrochloride (2 g) were dissolved in distilled water for injection (80 ml). After being adjusted to pH 6 by adding a sufficient quantity of sodium hydroxide, the solution was added with distilled water for injection up to the total volume of 100 ml to prepare a composition for local anesthesia.
- Hydroxyzine hydrochloride (2.5 g) and lidocaine hydrochloride (2 g) were dissolved in distilled water for injection (80 ml). After being adjusted to pH 6 by adding a sufficient quantity of hydrochloric acid, the solution was added with distilled water for injection up to the total volume of 100 ml to prepare a composition for local anesthesia.
- Lidocaine hydrochloride (2 g) was dissolved in distilled water for injection (80 ml). After being adjusted to pH 6 by adding a sufficient quantity of sodium hydroxide, the solution was added with distilled water for injection up to the total volume of 100 ml to prepare a composition for local anesthesia.
- Diphenhydramine hydrochloride (3 g) was dissolved in distilled water for injection (80 ml). After being adjusted to pH 6 by adding a sufficient quantity of sodium hydroxide, the solution was added with distilled water for injection up to the total volume of 100 ml to prepare a composition for local anesthesia.
- lidocaine hydrochloride 2 g
- epinephrine hydrogen tartrate 2.5 mg
- sodium pyrosulfite 60 mg
- composition for local anesthesia of the present invention provides increased anesthetic depth and durability of local anesthesia without using catecholamines such as epinephrine, and is useful as a safe composition for local anesthesia used for short-time dental operations such as tooth extraction and oral surgery operations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002357823 | 2002-12-10 | ||
JP2002357823 | 2002-12-10 | ||
PCT/JP2003/015794 WO2004052399A1 (fr) | 2002-12-10 | 2003-12-10 | Composition destinee a une anesthesie topique |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1582220A1 true EP1582220A1 (fr) | 2005-10-05 |
EP1582220A4 EP1582220A4 (fr) | 2007-07-25 |
Family
ID=32500874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03778778A Withdrawn EP1582220A4 (fr) | 2002-12-10 | 2003-12-10 | Composition destinee a une anesthesie topique |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060216245A1 (fr) |
EP (1) | EP1582220A4 (fr) |
JP (1) | JPWO2004052399A1 (fr) |
KR (1) | KR20050086903A (fr) |
AU (1) | AU2003289011A1 (fr) |
WO (1) | WO2004052399A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8142592B2 (en) | 2008-10-02 | 2012-03-27 | Mylan Inc. | Method for making a multilayer adhesive laminate |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010050211A1 (fr) | 2008-10-30 | 2010-05-06 | 国立大学法人 岡山大学 | Composition destinée à une anesthésie locale |
FR2962040B3 (fr) | 2010-07-05 | 2012-08-10 | Alain Villette | Composition injectable comprenant un medicament injectable et un gel |
US11577019B2 (en) * | 2020-10-01 | 2023-02-14 | Ken Marenco | Administration of a vaccine or emergency administration of a medicament using a dental carpule |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4748022A (en) * | 1985-03-25 | 1988-05-31 | Busciglio John A | Topical composition |
EP0320254A1 (fr) * | 1987-12-09 | 1989-06-14 | Thames Pharmacal Co.Inc. | Gels aqueux contenant des médicaments topiques |
US5008289A (en) * | 1988-12-02 | 1991-04-16 | Galenpharma, Inc. | Composition for treating nasal disorders and headaches |
US5543148A (en) * | 1994-07-12 | 1996-08-06 | Combe, Incorporated | Stick delivery system for topical application of a treatment agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659714A (en) * | 1984-03-27 | 1987-04-21 | Dentsply, Ltd. | Anesthetic methods for mammals |
JPH0774152B2 (ja) * | 1989-07-27 | 1995-08-09 | 株式会社大塚製薬工場 | 皮膚外用液剤 |
DK0694310T3 (da) * | 1993-04-16 | 2000-06-05 | Wakamoto Pharma Co Ltd | Reversibelt, termisk gelatinerende, vandbaseret, medicinsk præparat |
US5505922A (en) * | 1993-08-13 | 1996-04-09 | University Of Maryland At Baltimore | Anesthetic pharmaceutical combination |
JP3487633B2 (ja) * | 1994-04-28 | 2004-01-19 | 祐徳薬品工業株式会社 | 皮膚疾患治療乳剤 |
WO1997007794A1 (fr) * | 1995-08-28 | 1997-03-06 | Showa Yakuhin Kako Co., Ltd. | Composition pour anesthesie locale |
US5912007A (en) * | 1996-02-29 | 1999-06-15 | Warner-Lambert Company | Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same |
JP4176858B2 (ja) * | 1998-02-18 | 2008-11-05 | 久光製薬株式会社 | エアゾール製剤 |
TWI243687B (en) * | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
JP4820024B2 (ja) * | 2001-01-10 | 2011-11-24 | 昭和薬品化工株式会社 | 局所麻酔用組成物 |
-
2003
- 2003-12-10 AU AU2003289011A patent/AU2003289011A1/en not_active Abandoned
- 2003-12-10 WO PCT/JP2003/015794 patent/WO2004052399A1/fr active Application Filing
- 2003-12-10 JP JP2004558457A patent/JPWO2004052399A1/ja active Pending
- 2003-12-10 US US10/538,061 patent/US20060216245A1/en not_active Abandoned
- 2003-12-10 KR KR1020057010325A patent/KR20050086903A/ko not_active Application Discontinuation
- 2003-12-10 EP EP03778778A patent/EP1582220A4/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4748022A (en) * | 1985-03-25 | 1988-05-31 | Busciglio John A | Topical composition |
EP0320254A1 (fr) * | 1987-12-09 | 1989-06-14 | Thames Pharmacal Co.Inc. | Gels aqueux contenant des médicaments topiques |
US5008289A (en) * | 1988-12-02 | 1991-04-16 | Galenpharma, Inc. | Composition for treating nasal disorders and headaches |
US5543148A (en) * | 1994-07-12 | 1996-08-06 | Combe, Incorporated | Stick delivery system for topical application of a treatment agent |
Non-Patent Citations (1)
Title |
---|
See also references of WO2004052399A1 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8142592B2 (en) | 2008-10-02 | 2012-03-27 | Mylan Inc. | Method for making a multilayer adhesive laminate |
US9731490B2 (en) | 2008-10-02 | 2017-08-15 | Mylan Inc. | Method for making a multilayer adhesive laminate |
US10272656B2 (en) | 2008-10-02 | 2019-04-30 | Mylan Inc. | Method for making a multilayer adhesive laminate |
Also Published As
Publication number | Publication date |
---|---|
US20060216245A1 (en) | 2006-09-28 |
WO2004052399A1 (fr) | 2004-06-24 |
EP1582220A4 (fr) | 2007-07-25 |
KR20050086903A (ko) | 2005-08-30 |
AU2003289011A1 (en) | 2004-06-30 |
JPWO2004052399A1 (ja) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8648056B2 (en) | Composition for local anesthesia | |
US10881647B2 (en) | Neosaxitoxin combination formulations for prolonged local anesthesia | |
AU756120B2 (en) | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds | |
JP2003532678A (ja) | 局所麻酔の方法およびキット | |
AU2016266058A1 (en) | S1P receptor modulators for treating multiple sclerosis | |
ES2861064T3 (es) | Anestésico dental que comprende tetracaína y un vasoconstrictor para administración intranasal | |
ATE432689T1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
WO2002022128A1 (fr) | Methode d'anesthesie et d'analgesie locales | |
EP1582220A1 (fr) | Composition destinee a une anesthesie topique | |
Rioja et al. | Cardiorespiratory and minimum alveolar concentration sparing effects of a continuous intravenous infusion of dexmedetomidine in halothane or isoflurane-anaesthetized rats | |
EP0728479A1 (fr) | Désacétyl moxisylyte dans le traitement des rétentions aigues d'urine | |
US20240238224A1 (en) | Composition for local anaesthesia and uses thereof | |
Domingo et al. | Local anesthetics: review of pharmacologic aspects and clinical properties | |
JP2005255663A (ja) | 局所麻酔用組成物 | |
UA119260C2 (uk) | Ін'єкційна гелеподібна водна композиція для проведення місцевої анестезії | |
Rajalakshmi | A Clinical Comparision Between 0.25% Bupivacaine and 0.25% Bupivacaine Tramadol (2mg/Kg) Combination in Brachial Plexus Block by Supraclavicular Approach | |
JPH0710753A (ja) | 注射剤 | |
JPH11310529A (ja) | 局所麻酔剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050614 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070625 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
17Q | First examination report despatched |
Effective date: 20090918 |
|
18D | Application deemed to be withdrawn |
Effective date: 20091229 |